Verastem to Acquire Cyclacel Pharmaceuticals
Ticker: BGMSP · Form: 8-K · Filed: Sep 6, 2024 · CIK: 1130166
| Field | Detail |
|---|---|
| Company | Cyclacel Pharmaceuticals, INC. (BGMSP) |
| Form Type | 8-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, definitive-agreement
TL;DR
Verastem is buying Cyclacel, deal expected to close Q4 2024.
AI Summary
Cyclacel Pharmaceuticals, Inc. announced on September 4, 2024, that it has entered into a definitive agreement to be acquired by Verastem, Inc. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition aims to combine Cyclacel's pipeline with Verastem's existing portfolio.
Why It Matters
This acquisition could lead to the consolidation of drug development pipelines in the oncology space, potentially impacting the future availability and development of specific cancer therapies.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, which introduces uncertainty regarding its completion.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- Verastem, Inc. (company) — Acquiring company
- September 4, 2024 (date) — Date of earliest event reported
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing reports on the entry into a definitive agreement for the acquisition of Cyclacel Pharmaceuticals, Inc. by Verastem, Inc.
Who is acquiring Cyclacel Pharmaceuticals, Inc.?
Verastem, Inc. is acquiring Cyclacel Pharmaceuticals, Inc.
When is the acquisition expected to close?
The acquisition is expected to close in the fourth quarter of 2024.
What are the conditions for the closing of the acquisition?
The acquisition is subject to customary closing conditions.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is September 4, 2024.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 12.1 · Accepted 2024-09-06 16:01:21
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital Ma
Filing Documents
- tm2423533d1_8k.htm (8-K) — 25KB
- 0001104659-24-097731.txt ( ) — 238KB
- cycc-20240904.xsd (EX-101.SCH) — 3KB
- cycc-20240904_def.xml (EX-101.DEF) — 26KB
- cycc-20240904_lab.xml (EX-101.LAB) — 36KB
- cycc-20240904_pre.xml (EX-101.PRE) — 25KB
- tm2423533d1_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On September 4, 2024, the Board of Directors of Cyclacel Pharmaceuticals, Inc. (the "Company") passed a resolution to suspend payment of the quarterly cash dividend on the Company's 6% Convertible Exchangeable Preferred Stock (the "Preferred Stock") scheduled for November 1, 2024. The Board of Directors will continue to evaluate the payment of a quarterly cash dividend on a quarterly basis.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYCLACEL PHARMACEUTICALS, INC. By: /s/ Paul McBarron Name: Paul McBarron Title: Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer Date: September 6, 2024